Anergis And Virometix Collaborate On Fast-Acting Allergy Immunotherapy
Combining Synthetic Virus-Like Particles With Contiguous Overlapping Peptides
Executive Summary
An ultra-fast-acting allergy immunotherapy to induce tolerance to house dust mites is being sought in a collaboration between two Swiss biotechs, Anergis and Virometix.
You may also be interested in...
Allergy Therapeutics Takes First Steps Into Broader Vaccine Field
Allergy Therapeutics is keen to extend its early R&D pipeline into non-allergy areas through extending its tie-up with Saiba and DeepVax on their virus-like particle technology.
Deal Watch: Merck's Busy Stretch Includes Collaborations With Dewpoint, Zymeworks
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
Allergy Therapeutics Stumped As Birch Product Fails At Phase III
A strong immunological response to the PQ Birch vaccine did not translate into any appreciable reduction in symptoms in the Phase III trial, leaving the UK firm perplexed, and its share price southwards.